Education
About Us
Working with TipRanks
Follow Us
Inhibitor Therapeutics Inc. (INTI)
:INTI
INTI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.03 - $0.10
Previous CloseN/A
Volume30.00
Average Volume (3M)14.29K
Market Cap
$8.37M
Enterprise Value$19.94M
Total Cash (Recent Filing)$4.32M
Total Debt (Recent Filing)$84.35K
Price to Earnings (P/E)―
Beta1.76
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding172,323,550
10 Day Avg. Volume8,185
30 Day Avg. Volume14,293
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-8.20
Price to Sales (P/S)0.00
P/FCF Ratio-7.67
Enterprise Value/Market Cap2.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Inhibitor Therapeutics News
PremiumCompany Announcements
Tilaknagar Industries to Meet Analysts and InvestorsOptions Prices
Currently, No data available
---
Ownership Overview
14.98% Insiders
―
Mutual Funds
― Other Institutional Investors
85.02% Public Companies and
Individual Investors
INTI FAQ
What was Inhibitor Therapeutics Inc.’s price range in the past 12 months?
Inhibitor Therapeutics Inc. lowest stock price was $0.03 and its highest was $0.10 in the past 12 months.
What is Inhibitor Therapeutics Inc.’s market cap?
Inhibitor Therapeutics Inc.’s market cap is $8.37M.
When is Inhibitor Therapeutics Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Inhibitor Therapeutics Inc.’s earnings last quarter?
Inhibitor Therapeutics Inc. released its earnings results on May 01, 2018. The company reported -$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.003.
Is Inhibitor Therapeutics Inc. overvalued?
According to Wall Street analysts Inhibitor Therapeutics Inc.’s price is currently Overvalued.
Does Inhibitor Therapeutics Inc. pay dividends?
Inhibitor Therapeutics Inc. does not currently pay dividends.
What is Inhibitor Therapeutics Inc.’s EPS estimate?
Inhibitor Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inhibitor Therapeutics Inc. have?
Inhibitor Therapeutics Inc. has 172,323,550 shares outstanding.
What happened to Inhibitor Therapeutics Inc.’s price movement after its last earnings report?
Inhibitor Therapeutics Inc. reported an EPS of -$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Inhibitor Therapeutics Inc.?
Currently, no hedge funds are holding shares in INTI
Company Description
Inhibitor Therapeutics Inc.
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
Technical Analysis
Relmada Therapeutics
―
Predictive Oncology
―
Immuron
―
Intelligent Bio Solutions
―
Neuphoria Therapeutics
―